Frequently asked questions

It means the product is sold as a laboratory research chemical - not as a drug, supplement, or cosmetic - and is not approved for human or veterinary use. Two things buyers often get wrong about it:

First, the label is not a legal shield for sellers. Under the FDA's intended-use doctrine (21 CFR §201.128), regulators judge a product by how it is marketed and used, not by what the label says. In its warning letters of 24 August 2026 to five online sellers, the FDA pointed to exactly the surrounding content - benefit claims, dosing information and calculators, and reconstitution supplies sold alongside vials - as evidence of intended human use.

Second, that is why this site publishes no dosing, protocol, or usage content of any kind, and why a seller whose pages are full of it is showing you their regulatory risk profile, not their expertise.

No. The compounds covered on this site - MOTS-c, Semax, KPV, Epithalon and blends containing them - are not FDA-approved for any human use. Most have never been through FDA review. Any site implying otherwise is misdescribing the products it sells.

Three different answers, because "legal" covers three different activities - and as of October 2026 they point in different directions:

• Sold as research chemicals: the compounds are sold openly in the research-chemical channel under "research use only" labeling. The channel is policed through intended use - market a product for human use and the FDA treats it as an unapproved drug whatever the label says (21 CFR §201.128). That doctrine is what the August 2026 warning letters enforced.
• Compounded by pharmacies: not lawful for the compounds covered here. None of MOTS-c, Semax, KPV, or Epithalon is on the 503A Bulks List, so 503A pharmacies cannot lawfully compound them.
• Approved for human use: none of them, for any use.

State rules can add restrictions on top of the federal position described here.

On 23-24 July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six peptides for the 503A Bulks List, the list of substances licensed compounding pharmacies may use: BPC-157, TB-500 and KPV at 8-6-1; MOTS-c at 7-5-2; Semax at 8-5-1; Epithalon at 7-5-1. FDA staff had recommended against all seven compounds reviewed; the seventh, DSIP, was voted down.

What it changed in law, as of October 2026: nothing. The committee is advisory. The FDA has not added any of the six to the Bulks List, no rulemaking has been completed, and 503A pharmacies cannot lawfully compound them. A further committee session on a second group of compounds is expected by February 2027. Headlines that describe the July votes as "legalisation" are ahead of the facts.

Nobody outside the FDA knows, and as of October 2026 the agency has published no date. What has to happen is rulemaking: a compound joins the 503A Bulks List through a published FDA rule, and until a final rule takes effect, the legal position does not change - an advisory recommendation starts that process; it does not finish it. A second advisory session covering another group of compounds is expected by February 2027, which gives some sense of the pace. Anyone quoting a legalization date is guessing.

A certificate of analysis is the lab report for a specific batch of product. A meaningful COA has four properties: it names the batch or lot it covers; it comes from a third-party laboratory rather than the seller; it reports identity and purity testing by HPLC and mass spectrometry; and its results match the lot number on the vial you receive. A generic COA reused across products, with no lot number and no method stated, verifies very little. For blends such as GLOW and KLOW, each named component should be verified - see the KPV page.

Testing, warehousing, and an unstandardized market. Tracked October 2026 figures: 10 mg MOTS-c listings started at $15.31 across 252 vendors; BPC-157 at $19.16 across 241 vendors; Selank, the most commoditised compound here, sat at a $39.99 median across 200 vendors (PeptidePrices). The full tracked table is on the price-comparison page.

Deliberately, and for documented reasons. Retatrutide is an unapproved investigational drug; its developer, Eli Lilly, filed six lawsuits against sellers on 12 August 2026 and five more on 8 October, and referred over 200 sellers to the FDA and DOJ - search demand for it is enormous, and it is still not a product a responsible publisher builds a catalogue on. SS-31 (elamipretide) was approved by the FDA in September 2025 as the prescription drug Forzinity for Barth syndrome, which makes research-channel versions of it the clearest enforcement target in the catalogue - it was cited in four of the five August 2026 warning letters. DSIP was the only compound the July 2026 advisory committee voted not to recommend. High search volume is not the same thing as a sound product.

Mostly lyophilized (freeze-dried) vials - the standard format across the catalogue. Two compounds covered here are also commonly listed in nasal-format bottles: Semax (around $42) and Epithalon (around $52), both checked October 2026. A few compounds exist in capsule form in the compounding channel. A nasal bottle and a vial of the same compound are not interchangeable products, and they should not be price-compared as if they were; the formats differ in their research contexts, and vendor copy that blurs the distinction is hiding a real one. This site describes formats; it does not publish usage information for any of them.

ClearCost Wellness is published by Dataweave Inc. Our own store is fulfilled by a white-label partner under our brand. Links to partner stores - Bench Grade Peptides is the first - are affiliate links: they pay us a commission on referred sales at no extra cost to the buyer, and carry rel="sponsored nofollow". Commissions are disclosed at the top of every page and next to the links themselves, per FTC guidance. Full details on the affiliate disclosure page.

No. This site publishes educational and market information. It provides no dosing, protocol, or treatment information, makes no claims about what any compound does in humans, and is not a substitute for a licensed clinician.